DNA
Ginkgo Bioworks Holdings
NYSE: DNA · HEALTHCARE · BIOTECHNOLOGY
$9.70
+14.66% today
Updated 2026-05-01
Market cap
$551.05M
P/E ratio
—
P/S ratio
3.24x
EPS (TTM)
$-5.64
Dividend yield
—
52W range
$5 – $18
Volume
1.2M
Ginkgo Bioworks Holdings (DNA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
1 of 8
Last 8 quarters
Avg EPS surprise
-200.0%
Last 4 quarters
Revenue YoY growth
-23.8%
Most recent quarter
EPS YoY growth
+29.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-25.4%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-28.0%
2026-02-26
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-26 | $-1.42 | -1928.6% | $9.38 | $6.75 | -28.0% |
| 2025-11-06 | $-1.45 | -1511.1% | $11.59 | $8.95 | -22.8% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.07 | $-1.42 | -1928.6% | $33.40M | -23.8% |
| 2025-09-30 | $-0.09 | $-1.45 | -1511.1% | $38.84M | -56.4% |
| 2025-06-30 | $-0.10 | $-1.10 | -1000.0% | $49.60M | -11.7% |
| 2025-03-31 | $-0.08 | $-1.68 | -2000.0% | $48.32M | +27.3% |
| 2024-12-31 | $-0.06 | $-2.00 | -3330.5% | $43.85M | +26.2% |
| 2024-09-30 | $-0.07 | $-1.08 | -1483.6% | $89.05M | +60.6% |
| 2024-06-30 | $-0.08 | $-0.11 | -37.5% | $56.21M | -30.2% |
| 2024-03-31 | $-0.08 | $-0.08 | +0.0% | $37.94M | -53.0% |
| 2023-12-31 | $-0.10 | $-0.11 | -10.0% | $34.76M | — |
| 2023-09-30 | $-0.09 | $-0.16 | -77.8% | $55.43M | — |
| 2023-06-30 | $-0.08 | $-0.09 | -12.5% | $80.57M | — |
| 2023-03-31 | $-0.09 | $-0.11 | -22.2% | $80.70M | — |
Frequently asked questions
Has Ginkgo Bioworks Holdings beaten earnings estimates?
Ginkgo Bioworks Holdings has beaten Wall Street EPS estimates in 1 of its last 8 quarterly reports, with an average EPS surprise of -200.0% over the last 4 quarters.
How does DNA stock react to earnings?
DNA stock has moved an average of -25.4% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Ginkgo Bioworks Holdings's revenue growth rate?
Ginkgo Bioworks Holdings reported year-over-year revenue growth of -23.8% in its most recent quarter, with EPS growing +29.0% year-over-year.